FDA has approved the first human trial for Elon Musk's brain chip company Neuralink

5/25/2023

On Thursday, Neuralink, Elon Musk's brain-implant company, announced that it had obtained approval from the U.S. Food and Drug Administration (FDA) to commence its first clinical study involving human participants.

Elon Musk has repeatedly anticipated FDA approval for human trials for his brain-chip company since 2019. However, the company's application was rejected in early 2022, and they have been addressing the FDA's concerns regarding the safety of the experimental implant.

Neuralink expressed its appreciation for the collaborative efforts between their team and the FDA, describing this achievement as a significant initial milestone that will eventually enable their technology to assist numerous individuals. They clarified in a tweet on Thursday that they are not yet accepting participants for a clinical trial.

Neuralink aims to develop a brain implant that can potentially restore mobility to paralyzed individuals and provide remedies for various neurological conditions.

Reuters' request for comment from the U.S. FDA has not received an immediate response.

Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.

Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.

The Blubber

Trump has told Walmart, $WMT, to 'eat the tariffs' instead of raising prices

Moody’s downgrades US credit rating to Aa1 from Aaa

YouTube, GOOGL, viewers will start seeing ads after ‘peak’ moments in videos

CEOs say that just a fraction of AI initiatives are actually delivering the return on investment they expected

Stay Updated